Ververeli Charilila-Loukia, Dimitroglou Yannis, Soulaidopoulos Stergios, Cholongitas Evangelos, Aggeli Constantina, Tsioufis Konstantinos, Tousoulis Dimitris
1st Department of Cardiology, Hippokrateio General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Biomedicines. 2025 Mar 28;13(4):812. doi: 10.3390/biomedicines13040812.
: Chronic liver disease (CLD) and cirrhosis contribute to approximately 2 million deaths annually, with primary causes including alcohol-related liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic hepatitis B and C infections. Among these, MASLD has emerged as a significant global health concern, closely linked to metabolic disorders and a leading cause of liver failure and transplantation. : This review aims to highlight the interplay between cirrhosis and cardiac dysfunction, emphasizing the pathophysiology, diagnostic criteria, and management of cirrhotic cardiomyopathy (CCM). : A comprehensive literature review was conducted to evaluate the hemodynamic and structural cardiac alterations in cirrhosis. : Cirrhosis leads to portal hypertension and systemic inflammation, contributing to CCM, which manifests as subclinical cardiac dysfunction, impaired contractility, and electrophysiological abnormalities. Structural changes, such as increased left ventricular mass, myocardial fibrosis, and ion channel dysfunction, further impair cardiac function. Vasodilation in the splanchnic circulation reduces peripheral resistance, triggering compensatory tachycardia, while the activation of the renin-angiotensin-aldosterone system (RAAS) promotes fluid retention and increases cardiac preload. Chronic inflammation and endotoxemia exacerbate myocardial dysfunction. The 2005 World Congress of Gastroenterology (WCG) and the 2019 Cirrhotic Cardiomyopathy Consortium (CCC) criteria provide updated diagnostic frameworks that incorporate global longitudinal strain (GLS) and tissue Doppler imaging (TDI). Prolonged QT intervals and arrhythmias are frequently observed. Managing heart failure in cirrhotic patients remains complex due to intolerance to afterload-reducing agents, and beta-blockers require careful use due to potential systemic hypotension. The interaction between CCM and major interventions, such as transjugular intrahepatic portosystemic shunt (TIPS) and orthotopic liver transplantation (OLT), highlights the critical need for thorough preoperative cardiac evaluation and vigilant postoperative monitoring. : CCM is a frequently underdiagnosed yet significant complication of cirrhosis, impacting prognosis, particularly post-liver transplantation. Early identification using echocardiography and thorough evaluations of arrhythmia risk in cirrhotic patients are critical for optimizing management strategies. Future research should focus on targeted therapeutic approaches to mitigate the cardiac burden in cirrhotic patients and improve clinical outcomes.
慢性肝病(CLD)和肝硬化每年导致约200万人死亡,主要病因包括酒精性肝病(ALD)、代谢功能障碍相关脂肪性肝病(MASLD)以及慢性乙型和丙型肝炎感染。其中,MASLD已成为一个重大的全球健康问题,与代谢紊乱密切相关,是肝衰竭和肝移植的主要原因。:本综述旨在强调肝硬化与心脏功能障碍之间的相互作用,重点阐述肝硬化性心肌病(CCM)的病理生理学、诊断标准和管理。:进行了一项全面的文献综述,以评估肝硬化时心脏的血流动力学和结构改变。:肝硬化导致门静脉高压和全身炎症,进而引发CCM,表现为亚临床心脏功能障碍、收缩功能受损和电生理异常。结构变化,如左心室质量增加、心肌纤维化和离子通道功能障碍,进一步损害心脏功能。内脏循环血管扩张降低外周阻力,引发代偿性心动过速,而肾素-血管紧张素-醛固酮系统(RAAS)的激活促进液体潴留并增加心脏前负荷。慢性炎症和内毒素血症加剧心肌功能障碍。2005年世界胃肠病学大会(WCG)和2019年肝硬化性心肌病联盟(CCC)的标准提供了纳入全球纵向应变(GLS)和组织多普勒成像(TDI)的更新诊断框架。经常观察到QT间期延长和心律失常。由于对降低后负荷药物不耐受,肝硬化患者心力衰竭的管理仍然复杂,并且由于潜在的全身性低血压,β受体阻滞剂需要谨慎使用。CCM与经颈静脉肝内门体分流术(TIPS)和原位肝移植(OLT)等主要干预措施之间的相互作用,凸显了术前进行全面心脏评估和术后进行密切监测的迫切需求。:CCM是肝硬化常见但常被漏诊的重要并发症,影响预后,尤其是肝移植后。使用超声心动图进行早期识别以及对肝硬化患者心律失常风险进行全面评估对于优化管理策略至关重要。未来的研究应侧重于针对性的治疗方法,以减轻肝硬化患者的心脏负担并改善临床结局。